Autotelic Bio announced on the 28th that it signed a contract with ST Pharm for the manufacture and supply of Trabedersen for immunotherapy candidate 'ATB-301 (Trabedersen and IL-2 combination therapy)'.

ATB-301 has been recognized for its innovation as a next-generation immunotherapy agent, by receiving investment from the Chungbuk Creative Economy Innovation Center, selected by an R&D support project by TIPS program (Private Investment-led Technology Startup Support Project) and the Pharm Navi project by MFDS. 

Trabedersen is an antisense oligonucleotide that was specifically designed to target human TGF-β and was developed based on data showing the correlation between TGF-β overexpression and tumor progression.

ST Pharm is a company that specializes in contract development and manufacture, ranking third globally in the oligonucleotide sector, and is the only company in Korea with a GMP facility capable of producing oligonucleotides. In addition, it is producing and supplying products for MNCs such as GSK, Merck, Roche, Janssen, and Gliead.

An official from Autotelic Bio said, “Through the agreement with ST Pharm, Trabedersen will be produced in a manufacturing site with excellent quality and GMP system. The importance of this contract is that it has laid the foundation for the global expansion of ATB-301, taking one more step into the global market not only in terms of efficacy and safety, but also in terms of quality.”